| Date | Title | Description |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 07.08.2025 | Artbio Secures $132M to Accelerate Precision Cancer Therapies | Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri... |
| 07.08.2025 | ARTBIO: $132 Million Series B Raised For New Class Of Alpha Radioligand Therapies | ARTBIO, a clinical-stage radiopharmaceutical company, is focused on developing alpha radioligand therapies (ARTs) for various types of cancer. The company has secured $132 million in Series B financing, co-led by new investors Sofinnova Inv... |
| 14.04.2025 | Atsena Therapeutics: $150 Million (Series C) Closed To Advance Ocular Gene Therapy Programs | Atsena Therapeutics – a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness – recently announced the closing of an oversubscribed $150 million Series C fnuding.... |
| 04.04.2025 | Atsena Therapeutics Raises $150M in Series C Financing | Atsena Therapeutics, a Durham, NC-based clinical-stage gene therapy company, raised $150M in Series C funding.
The round was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management... |
| 02.04.2025 | Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow | Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market approval.
The funding ro... |
| 19.03.2025 | Weatherford Capital Closes Fund II | Weatherford Capital, a Tampa, FL-based private investment firm, closed its Fund II, at $300M.
Led by Will Weatherford, Managing Partner, Weatherford Capital is a family-owned private investment firm that prioritizes businesses across the te... |
| 07.03.2025 | €450M to drive green data infrastructure, the next startup hub, and key trends and investment in February | This week we tracked more than 70 tech funding deals worth over €1.3 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe.
This week we also released Tech.eu Pulse, a compact version of our monthl... |
| 01.03.2025 | European Innovation Council Fuels DeepTech Revolution with Major Investments | In the heart of Europe, innovation is blossoming. The European Innovation Council (EIC) is leading the charge, injecting substantial funds into groundbreaking technologies. Two companies, QDI Systems and NanoPhoria, are at the forefront of ... |
| 26.02.2025 | NanoPhoria: €17.5 Million Awarded For Non-Viral Drug Delivery Platform | NanoPhoria, a pre-clinical stage biotech company developing a versatile and non-viral drug delivery platform based on inorganic nanoparticles with a lead product for heart failure treatment, announces the investment commitment of €17.5 mill... |
| 13.02.2025 | Latent Labs: The New Frontier in Programmable Biology | In the world of biotechnology, a new player has emerged, ready to rewrite the rules. Latent Labs, a London-based startup, has burst onto the scene with a staggering $50 million in funding. This infusion of capital is not just a number; it’s... |
| 13.02.2025 | AI pioneer Dr Simon Kohl's Latent Labs emerges from stealth, raising $50M for programmable biology | AI foundation model builder Latent Labs today emerged from stealth with $50 million in total funding to accelerate their progress in programmable biology.
The company was founded by Dr Simon Kohl, previously a co-lead of DeepMind’s protein ... |
| 14.01.2025 | Bioptimus brings its funding to $76M for the GPT of biology | AI foundation model company Bioptimus has raised a further $41 million cash injection, bringing its funding to $76 million.
Bioptimus is redefining how we approach biological research by addressing a longstanding issue: the siloed nature of... |
| 27.12.2024 | So können VCs den Impact von Startups messen | Gemeinsam mit führenden europäischen VC-Fonds wie ETF Partners, Sofinnova Partners, Astanor und SET Ventures haben wir bei FoodLabs als Teil der Coalition for Impact in Venture das Handbuch “Impact Accountability in Venture Capital: A Ready... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChr... |
| 11.12.2024 | Noema Pharma extends Series B funding to CHF 130 million |
EQT Life Sciences’ LSP 7 fund has invested in Noema Pharma. The clinical-stage biotech company headquartered in Basel is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series... |
| 11.12.2024 | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million
Wed, Dec 11, 2024 09:30 CET Report this content
Proceeds will be used to enable key late-stage clinical trial readouts for asset... |
| 22.10.2024 | Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines | Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a... |
| 11.10.2024 | Investment Climate Podcast: Giuseppe Scionti of NovaMeat | In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding alt proteins in 2024 and uncovers the investment playbooks of successful climate tech CEOs and leading VCs.
Podcast Host Alex Shandrovksy is a strate... |
| 23.09.2024 | Arzeda: Protein Design Company Closes $38 Million In Funding | Protein design company Arzeda announced it has raised $38 million in funding. This funding round includes new investments from Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and the venture arm of W.L. Gore & Assoc... |
| 18.09.2024 | Arzeda Raises $38M in Funding | Arzeda, a Seattle, WA-based protein design company,raised $38M in funding.
The round was led by Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and the venture arm of W.L. Gore & Associates. Previous investors also ... |
| 12.09.2024 | Novameat's €17.4M Funding: A Leap into the Future of Plant-Based Meat | In the bustling heart of Barcelona, a culinary revolution is brewing. Novameat, a pioneering plant-based meat startup, has secured €17.4 million in a Series A funding round. This investment, led by Sofinnova Partners and Forbion via its Bio... |
| 12.09.2024 | Novameat Secures €17.4M in Oversubscribed Round, Launches Improved Shredded Plant-Based Beef | Barcelona’s Novameat, a B2B company specializing in different cuts of plant-based chicken, beef, and turkey, announces it has raised €17.4 million in an oversubscribed Series A round led by Sofinnova Partners and Forbion via its BioEconomy ... |
| 12.09.2024 | Novameat Closes $19.2M Series A Round, Revamps Plant-Based Shredded Beef with Better Texture | 5 Mins Read Spain’s Novameat has attracted €17.4M in a Series A funding round to expand its plant-based meat range based on MicroForce technology, starting with a revamped shredded beef offering.
Catalan food tech startup Novameat has recei... |
| 12.09.2024 | Novameat raises $19.2m to expand next-gen plant-based meat texturizing tech: ‘We have a clear path to profitability’ | Barcelona-based plant-based meat startup Novameat has raised a €17.4m ($19.2 million) series A round.
Sofinnova and Forbion BioEconomy led the round, supported by existing investors Praesidium, Unovis Asset Management and Rubio Impact Ventu... |
| 27.07.2024 | Micropep's Leap: Transforming Agriculture with Micropeptide Innovation | In the world of agriculture, innovation is the lifeblood. It’s the spark that ignites change. Micropep Technologies is a shining example of this principle. Recently, the company secured $29 million in Series B funding, pushing its total fun... |
| 25.07.2024 | Micropep: Micropeptide Technology Leader Raises $29 Million | Micropep Technologies – a global leader in micropeptide technology, announced today a $29 million Series B funding round along with its proprietary discovery platform Krisalix. This funding round was led by Zebra Impact Ventures, and BPI Gr... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
Tue, Jul 16, 2024 09:15 CET Report this content
EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 28.05.2024 | Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas | Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas
Tue, May 28, 2024 08:15 CET Report this content
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER T... |
| 12.03.2024 | Nvidia стала делать ставку на все технологии, связанные с ИИ. За год компания инвестировала в 30 стартапов $1,55 млрд... | Последний год для производителя чипов Nvidia стал поворотным, поскольку он превзошел все ожидания и к концу февраля достиг рыночной капитализации более $2 трлн. Это сделало компанию крупнейшей по рыночной капитализации после Microsoft и App... |
| 11.03.2024 | It's not just chips. Nvidia is betting on other tech that could be impacted by AI. | Tech It's not just chips. Nvidia is betting on other tech that could be impacted by AI.
Lloyd Lee
2024-03-11T03:42:26Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An envelope. It indicate... |
| 27.10.2023 | Sofinnova Partners raises $200m for maiden digital medicine fund | - |
| 01.04.2020 | Sofinnova Investments Adds Jonathan Leff as Executive Partner | Sofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, added Jonathan Leff, M.D. to the investment team as an Executive Partner.
With more than 25 years of clinical development experience in the biot... |
| 31.03.2020 | Sofinnova Investments Promotes Two | Sofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, promoted Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner.
Maha Katabi, PhD, CFA who joined Sofinnova in April 2019, ha... |
| 18.03.2020 | Sofinnova Investments Adds Jonathan Leff as Executive Partner | Sofinnova Investments, a clinical stage biopharmaceutical investment firm, added Jonathan Leff, M.D. to the investment team as an Executive Partner.
With more than 25 years of clinical development experience in the biotechnology and pharmac... |
| 17.10.2019 | Sofinnova Partners raises $370.3 million for its early-stage healthcare fund to invest in healthtech and life sciences startups | Investments in healthcare and Life Sciences startups continue to soar. Now, the sector is boosted by today’s announcement from Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in L... |
| 22.04.2019 | Sofinnova Investments Adds Maha Katabi as a Partner | Maha Katabi, PhD.
Sofinnova Investments, a Menlo Park, Calif.-based clinical stage biopharmaceutical investment firm, added Maha Katabi, PhD. to the investment team as a Partner.
Maha Katabi, PhD., is an experienced investor in biopharma co... |
| 28.03.2019 | Polyneuron Raises CHF22.5 M for Autoimune Diseases | |
| 02.08.2017 | NEA Joins $67M Series C for Amplyx Pharmaceuticals | Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other n... |
| 23.05.2017 | Term Sheet — Tuesday, May 23 | FALSE START
Good morning – today’s column didn’t come together in time. Back tomorrow!
• Can China Save Hollywood?
Paid Content What you need to know about growing cyberattacks From ExtraHop
• The Fortune 100 Companies Doing the Most to Sto... |
| 23.03.2017 | Ysios Capital lidera una ronda de $30M en BioClin Therapeutics junto con Sofinnova Ventures | 23/03/2017
Nota de prensa
YSIOS LIDERA UNA RONDA DE $30 MILLONES EN BIOCLIN THERAPEUTICS JUNTO CON SOFINNVA VENTURES.
La entidad de capital riesgo (venture capital)Ysios Capital, ha liderado la ronda de financiación de serie B – por un i... |
| 16.03.2017 | Agtech Funding Sheet: Leonardo DiCaprio invests in LoveTheWild, ProducePay raises $7m | LoveTheWild, the Boulder-based frozen seafood brand that only sources farmed fish, has closed an undisclosed Series A round of funding with Leonardo DiCaprio and seafood-focused venture capital fund Aqua-Spark. The fund invested $2.5 millio... |
| 16.03.2017 | Agtech Funding Sheet: Leonardo DiCaprio Invests in LoveTheWild, ProducePay Raises $7m Series A, more | LoveTheWild, the Boulder-based frozen seafood brand that only sources farmed fish, has closed an undisclosed Series A round of funding with Leonardo DiCaprio and seafood-focused venture capital fund Aqua-Spark. The fund invested $2.5 millio... |
| 09.03.2017 | Belgian Startup Using Llama Antibodies for Biopesticides Increases Series B to $11.6m | AgroSavfe, a Belgian agro-biotech company that is developing a new generation of biopesticides, has increased its Series B financing round to $11.6 million. The bulk of the additional investment was provided by the Paris-based venture capit... |
| 22.01.2017 | France, The New Wave of Venture Capital Funds | France is emerging as one of the most active European countries in terms of venture capital investment activity.
A trend confirmed by the latest official data available. During the first half of 2016, €5.5 billion were invested in more than... |
| 28.11.2016 | Galera Therapeutics Receives $15M from Sofinnova Ventures | Galera Therapeutics, Inc., a Malvern, PA-based clinical-stage biotechnology company developing new treatments for cancer patients, received $15m in funding from new backer Sofinnova Ventures.
The investment brought the total amount raised i... |
| 17.10.2016 | Sofinnova Closes Latest Venture Capital Fund, at $650M | Sofinnova, a Menlo Park, CA-based biotech-focused investment firm, closed its latest fund, at $650M.
Sofinnova Venture Partners X, whose initial target was $550M, is the fourth fund to follow the firm’s strategy of investing in mid and late... |
| 26.08.2016 | Sofinnova Ventures has raised $595M for its largest fund to date | The company’s strategy of investing in late-stage private companies has found some receptive buyers for those businesses, demonstrated by acquisitions of its portfolio companies from the likes of Teva, Shire and Pfizer.
And yet, it has also... |
| 08.04.2016 | MedDay raises $38.5M to kick off U.S. clinical trials for multiple sclerosis | “The SPI2 study is expected to confirm, in a large North American population, the results of our prior European MS-SPI study and will further advance MedDay in the field of progressive MS worldwide,” CEO Frédéric Sedel said in a statement.
... |
| 24.03.2016 | Daily funding roundup - March 24, 2016 | Mesophere received $73.5M investment; Iterum Therapeutics secured $40M; Lagou completed Series C
Malaysia-based Nuren Group, a company that runs a number of women-dedicated content and e-commerce websites, raised $2 million in a Series A ro... |
| 06.01.2016 | Daily funding roundup - January 6, 2016 | Flatiron Health bagged $175M; NextCure, Inc. raised $67M; AirCloset received $8M funding
Ossia, a Bellevue, WA-based maker of a wireless power technology, received a strategic investment from Molex, LLC, a global manufacturer of electronic ... |
| 31.12.2015 | HealthQuest raising new $175M medtech fund | From the first fund, Healthquest Partners has made seven investments in medtech startups, including arthroscopy diagnostics maker Trice Medical, specialty drug health IT startup VirMedica, and First Aid Shot Therapy – a consumer-facing star... |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| 18.11.2015 | Daily funding roundup - November 18, 2015 | Ola bagged $500M; Joyable raised $8M; Test IO landed $5M
TestCloud, a self-service crowdtesting platform for app and Web developers, has a new name and a big new round of funding, the company announced on Wednesday, all to facilitate a big ... |
| 18.11.2015 | First Aid Shot Therapy® (F.A.S.T) Completes $24 million Series C Financing | BURLINGAME, Calif., Nov. 18, 2015 /PRNewswire/ — First Aid Shot Therapy® (F.A.S.T.), a consumer healthcare company focused on over-the-counter (OTC) medicine in liquid shot form (40ml / 1.35oz.), announced today that it has completed a Seri... |
| 13.10.2015 | Daily funding roundup - October 13, 2015 | EverString raised $65M; Audentes Therapeutics bagged $65M; SteelBrick received $48M
Predictive marketing company EverString has raised $65 million, in what is the largest round ever for an AI company. Lightspeed Venture Partners led the Com... |
| 29.09.2015 | Asceneuron raises CHF 30 million | |
| 12.08.2015 | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | Checkmate Pharmaceuticals operates on the idea that checkpoint inhibitor therapies would be much more effective if they were combined with an agent that could stimulate a person’s immune response. So, on top of the new financing, it’s also ... |
| 12.08.2015 | Daily funding roundup - August 12, 2015 | PokitDoc closed $34M; Infogain secured $63M; Soothe raised $10.6M
If there's a service that I often book with little time in advance, it's getting a massage. It's hard to predict when you're neck or back will ache, and when you have a free ... |
| 21.07.2015 | Daily funding roundup - July 21, 2015 | Bright.md raises $3.5M; Medallia bagged $150M; BrightBytes landed $33M
Bright.md, which makes software that enables communication between doctors and patients, closed a $3.5 million Series A funding round. Oregon Angel Fund led the round, w... |
| 06.04.2015 | Natera Raises $55.5M | Natera, Inc., a San Carlos, Calif.-based genetic testing company, raised approximately $55.5m in funding.
The round was led by Sofinnova Ventures with participation from Capital Research and Management, Franklin Templeton Investments, Jenni... |
| 02.10.2014 | Aclaris Therapeutics Closes $21M Series B Financing | Aclaris Therapeutics, Inc., a Malvern, Pennsylvania-based specialty pharmaceutical company, closed on a $21m Series B financing.
Backers included existing investors Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures.
Founded in Augu... |
| 19.08.2014 | HealthQuest Capital raises $110M for healthcare investments | HealthQuest Capital is looking to make some moves healthcare with its newly raised $110 million fund, looking for unmet needs in medical devices, diagnostics and information technology.
The Sofinnova Ventures-backed investment group garnere... |
| 23.07.2014 | Sofinnova Ventures Closes Ninth Fund at $500M | Sofinnova Ventures, a Menlo Park based investment firm dedicated to life science, closed its ninth fund at $500m.
Led by Srini Akkaraju, MD, PhD, Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Lars Ekman, MD, PhD, David Kabakoff, Ph... |
| 10.07.2014 | Sofinnova appears to be bulking up a healthcare venture fund to $110 million | Sofinnova Ventures has a robust active portfolio. Some of its more notable funding rounds include participation in a $72.8 million Series B round with Spark Therapeutics, a $55 million C round with Coherus Bio Sciences and a $50 million rou... |
| 11.02.2014 | First Aid Shot Therapy Completes Series B Financing Round | First Aid Shot Therapy (F.A.S.T.), a Burlingame, California-based consumer healthcare company, completed its Series B financing round.
The round – of undisclosed amount – was co-led by Sofinnova Ventures and Redmile Group with participation... |
| 10.02.2014 | First Aid Shot Therapy Snares Series B |
BURLINGAME, CA, Consumer healthcare company has completed a Series B financing round co-led by Sofinnova Ventures and Redmile Group.
>> Click here for more funding data on First Aid Shot Therapy (F.A.S.T.)
>> To export First... |
| 08.10.2013 | Versartis Completes $20M Series D Financing | Versartis, Inc., a Redwood City, CA-based biotechnology company developing novel therapeutics for patients with endocrine disorders, completed a $20m Series D financing.
The round was led by new investor Sofinnova Ventures, with participati... |
| 29.08.2013 | ObsEva SA announces CHF 32 Million funding | |
| 29.08.2013 | ObsEva Closes CHF32M Series A Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine, closed a CHF32m (approximately €25.6m) Series A financing round.
The round was led by Sofinnov... |
| 22.05.2013 | First Aid Shot Therapy Completes Series A Financing | First Aid Shot Therapy, Inc., a Burlingame, California-based consumer healthcare company focused on over-the-counter (OTC) therapies in liquid ‘shot’ (40ml / 1.35oz.) form, completed a Series A financing round.
The round, whose amount was n... |
| 22.05.2013 | First Aid Shot Therapy Completes Series A |
BURLINGAME, CA, Consumer healthcare company focused on over-the-counter (OTC) therapies in liquid form announced it has completed a Series A financing round led by Sofinnova Ventures.
>> Click here for more funding data on First Ai... |
| 17.04.2013 | Auris Medical Completes CHF47.1M Series C Financing | Auris Medical, a Basel, Switzerland-based biotechnology company that develops novel therapeutics for the treatment of inner ear disorders, completed a CHF47.1m Series C financing.
Backers included Sofinnova Ventures and Sofinnova Partners. ... |
| 16.04.2013 | Auris Medical secures CHF 47.1 mn Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development | Auris Medical secures CHF 47.1 mn Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development
April 16, 2013
Auris Medical, a company dedicated to t... |
| 16.04.2013 | Biggest Swiss financing round in 2013: CHF 47.1 mn for ground-breaking inner ear therapies | |
| 24.10.2012 | Dermatology therapeutics firm is born with $21M series A round | Stephen Tullman, who was an executive chairman with Vicept, will be the chairman of Aclaris’ board. Tullman currently serves as CEO of Ceptaris Therapeutics and managing partner of NeXeption, a biotechnology management company that identifi... |
| 24.10.2012 | Aclaris Therapeutics Secures $21M in Series A Financing | Aclaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company dedicated to developing dermatological therapeutics, has secured $21m in Series A financing.
The round was led by Vivo Ventures and Fidelity Biosciences with p... |
| 24.10.2012 | Mirna Therapeutics Completes $34.5M Series C Financing | Mirna Therapeutics Inc., an Austin, Texas-based biopharmaceutical company focused on the development and commercialization of microRNA (miRNA) therapeutics in cancer, has completed a $34.5m Series C financing.
The round was led by Sofinnova... |
| 18.10.2012 | Cebix Raises $30.9M in Series B Financing | Cebix, Inc., a La Jolla, California-based biopharmaceutical company developing treatments for complications of diabetes, has raised $30.9m in Series B financing.
Backers include existing investors InterWest, Sofinnova Ventures and Thomas, M... |
| 16.03.2012 | How Ireland stimulates venture capital investments | |
| 17.10.2011 | Sofinnova Ventures Closes Eight Fund at $440M | Sofinnova Ventures, a Menlo Park-based investment firm, has held the final close of its eight fund at $440m.
Sofinnova Venture Partners VIII will invest in later stage health care companies, with a specific focus on clinical stage drug deve... |
| 04.10.2011 | A resurgence in medical device IPOs? Don’t bet on it | Aside from recent volatility in the public markets, the problem for device firms is that valuations aren’t what they used to be. “Institutional investors just aren’t willing to pay up,” Mills said.
That’s good news for the venture arms of b... |
| 19.07.2010 | Kidney disease drug developer Sorbent Therapeutics raises $21M | “There’s no drug that removes clinically significant amounts of sodium and fluid on the market,” he said.
The trial is expected to wrap up early next year. Sorbent hopes to prove that the drug removes sodium from patients’ bodies and reduce... |
| 30.06.2010 | Vicept Therapeutics completes $16M Series A round | The funding round was led by California-based Vivo Ventures, California-based Sofinnova Ventures and Massachusetts-based Fidelity Biosciences, according to a statement from Vicept.
Vicept also plans to use the money to investigate other dru... |
| 06.07.2009 | Hyperion raises $60M to battle urea cycle disorders | Hyperion Therapeutics, developer of treatments for urea cycle disorders and illnesses, has brought in $60 million in a third round of financing from Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates an... |
| 22.06.2009 | CoAxia raises $21.5 million to complete trial of stroke device | CoAxia has spent the last four years enrolling patients in its 500-member pivotal trial to test NeuroFlo and expects to complete enrollment by early 2010, according to a company release.
This latest round, a Series D, was lead by French ven... |
| 18.05.2009 | Hyperion brings in $13M for gastrointestinal relief | Hyperion Therapeutics, maker of pharmaceuticals to treat hepatology and gastrointenstinal conditions, has raised $13 million of an anticipated $15 million round of debt, according to VentureWire. Contributors have not been disclosed, but th... |
| 09.04.2009 | Investors give up on diabetes drug maker DiObex | After failing to raise a sustaining round of capital, DiObex has been effectively shut down by its investors. They have laid off the San Francisco company’s eight employees and are moving to quickly sell off its assets, including its lead d... |
| 06.01.2009 | CES: CrestaTech will let laptops be universal TVs or radios | Personal computer hardware is not a segment of the tech industry where you’d expect to encounter any innovation. That’s why cell phone startups are far more plentiful than PC startups. But a new Silicon Valley company has taught the old dog... |
| 04.12.2008 | Catalyst lands $40M to combat disease-causing proteins | Catalyst Biosciences has raked in $40.4 million in third-round funding to continue engineering an enzyme called protease to fight disease-causing proteins. The technology has the potential to affect many different diseases, including cancer... |
| 24.10.2008 | Phenomix cancels IPO, finds new lab partner | Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January.
Fo... |
| 06.10.2008 | Crocus snags $15.8M to develop magnetic memory chips | French semiconductor maker Crocus Technology has raised $15.8 million in second round financing, in addition to $4.1 million from OSEO, France’s public agency for funding innovation.
The company plans to use the round for continued developm... |
| 14.08.2008 | Anthera Pharmaceuticals raises $19M for anti-inflammatory drugs | Anthera Pharmaceuticals has raised $19 million in a second round of funding led by Caxton Advantage Life Sciences Fund and HBM BioCapital. Existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi ... |
| 24.06.2008 | Alvine Pharmaceuticals raises $26 million for disease research | San Carlos, Calif. company Alvine Pharmaceuticals recently added $5 million to its first venture round, bringing total funding to $26 million, according to VentureWire.
Alvine’s research focuses on treatment for autoimmune and gastrointesti... |
| 12.05.2008 | Funambol and Laszlo Systems team up on open source mobile-web messaging | The web and mobile phones are getting hitched. That’s evident in a deal being announced today between start-ups Funambol and Laszlo Systems.
Funambol, based in Redwood City, Calif., makes mobile messaging software based on open source softw... |
| 23.01.2008 | Europe 2.0: European tech investing "coming of age," as events hard-wire the network | It’s mildly diverting when some say that Europe is still a slow place for technology startups, then pat us on the head and tell us that every day, in every way, we’re getting better and better. But it’s more interesting when people who real... |
| 23.01.2008 | European tech investing is "coming of age" | It’s mildly diverting when some people, like Business Week reporters, say that Europe is still a slow place for technology startups, then pat us on the head and tell us that every day, in every way, we’re getting better and better. But it’s... |
| 24.07.2007 | KaloBios draws in $20M for antibody drugs | KaloBios, a Palo Alto, Calif., biotech antibody-therapeutic company, raised $20 million in a third funding round. The company is developing new drugs based on monoclonal antibodies, which target specific cells or proteins in the body. Its l... |